Status:

TERMINATED

Efficacy of Ocrelizumab in Autoimmune Encephalitis

Lead Sponsor:

University of Texas Southwestern Medical Center

Collaborating Sponsors:

Genentech, Inc.

Conditions:

Autoimmune Encephalitis

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This pilot study is a randomized, double-blind, placebo controlled study of the efficacy of ocrelizumab in autoimmune encephalitis. Subjects with new diagnosis of autoimmune encephalitis will be invit...

Eligibility Criteria

Inclusion

  • Age 18 or greater
  • Able to obtain informed consent from patient or appropriate designee
  • Possible autoimmune encephalitis as defined by Table 1:
  • Reasonable exclusion of alternative causes
  • Subacute onset (\< 3 months) of memory deficits, altered consciousness, and/or psychiatric symptoms
  • One or more of the following:
  • CSF (cerebrospinal fluid) pleocytosis (\>5 cells/µl corrected, if necessary, for traumatic lumbar puncture)
  • EEG (electroencephalogram) with epileptiform or focal slow wave abnormalities involving temporal lobes
  • Brain abnormalities on T2/FLAIR MRI restricted to the mesial temporal (limbic) lobes
  • Associated dyskinesias (faciobrachial dystonic movements or orofacial dyskinesias)
  • Completed initial treatment with iv steroids (at least 3000mg solumedrol) and plasma exchange (at least 3 exchanges) within the past 8 weeks
  • Presence of one (or more) of the following autoantibodies in serum or CSF
  • NMDA receptor
  • LGI1
  • CASPR2
  • DPPX

Exclusion

  • Prior immunosuppression treatment in past year (other than steroids, intravenous immunoglobulin and plasma exchange)
  • Active malignancy requiring chemotherapy
  • Pregnancy
  • Evidence of active hepatitis or tuberculosis infection
  • Medical condition that (in investigators opinion) precludes the use of ocrelizumab

Key Trial Info

Start Date :

January 22 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 2 2020

Estimated Enrollment :

3 Patients enrolled

Trial Details

Trial ID

NCT03835728

Start Date

January 22 2019

End Date

October 2 2020

Last Update

October 19 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

UT Southwestern Medical Center

Dallas, Texas, United States, 75390